ARTBIO的动态

Below are some exciting new EXECUTIVE appointments which have taken place recently over the last week. ???? ???? Innovent Biologics have appointed Nageatte Ibrahim, M.D. Ibrahim as their new CMO.? Athira Pharma have appointed Javier San Martin as their new CMO. ? Orna Therapeutics appointed Frank Neumann as their new CMO. ? Nuevocor have appointed John Lee MD PhD as their new CMO. ? FundaMental Pharma have appointed Dirk Beher their new CEO. ? TScan Therapeutics have appointed Chrystal U Louis, MD, MPH as their new CMO. ? Zura Bio Limited (Nasdaq: ZURA) have appointed Robert Lisicki as their new CEO. ? Gain Therapeutics have appointed Gene Mack as their new CFO. ? Xencor have appointed Bart Cornelissen as their new CFO. ? Pharvaris have appointed David Nassif as their new CFO. ? Terns Pharmaceuticals have appointed Melita Sun Jung as their new CBO. ? STALICLA have appointed Thomas Blaettler as their new CMO. ? Huge congratulations to all these incredible leaders from myself & everyone at Elixir Associates. ?? ?? ?? #Appointments #Leaders #Executive #Congratulations #News #Elixir #Leadership #Hiring #Medical #Regulatory #Clinical #DrugDevelopment #LifeSceinces #Healthcare #Pharma #DrugDevelopment #Biotech #Healthcare

Below are some exciting new EXECUTIVE appointments which have taken place recently over the last couple of weeks. ???? ???? Voyager Therapeutics, Inc. have appointed Toby Ferguson as their new CMO. ? IDRx have appointed Tim Clackson as their new CEO.? Rigel Pharmaceuticals Inc. have appointed Lisa Rojkjaer, MD as their new CMO. ? Hyku Biosciences have appointed Kleem Chaudhary as their new CEO. ? FibroGen, Inc. have appointed Deyaa Adib, MD as their new CMO. ? KalVista Pharmaceuticals, Inc. have appointed Ben Palleiko as their new CEO. ? Vast Therapeutics have appointed Paul Bruinenberg MD MBA as their new CMO. ? VedaBio have appointed Frederic D. Sweeney as their new CEO. ? MBrace Therapeutics have appointed Steve Alley as their new CSO. ? 4M Therapeutics Inc. have appointed Kimberly Lee, DO as their new CBO. ? Huge congratulations to these incredible leaders from myself & everyone at Elixir Associates. ?? ?? ?? #Appointments #Leaders #Executive #Congratulations #News #Elixir #Leadership #Hiring #Medical #Regulatory #Clinical #DrugDevelopment #LifeSceinces #Healthcare #Pharma #DrugDevelopment #Biotech

?????????KUDOS to?Inventiva Pharma,?Frederic Cren,?Jean VOLATIER,?Pierre Broqua,?Pascaline Clerc-Brenner, PhD?for the successful #PIPE of up to $410m. Namsen Capital?is proud to advise?Inventiva Pharma?in this landmark financing that will support the development of #Lanifibranor through potential New Drug Application.? Inventiva Pharma?is the most advanced?#european?#biotech?in the?#NASH?disease therapeutics' field?while evaluating?#Lanifibranor?in?#NATiV3, a phase 3 clinical trial lead across 19 countries. #Financing co led by New Enterprise Associates (NEA), BVF PARTNERS, L.P and Samsara BioCapital, with the participation of Andera Partners, DeepTrack, Eventide Asset Management, Great Point Partners, The Invus Group, Perceptive Advisors, Schonfeld and Sofinnova Partners. J.P. Morgan Cowen Inc. Guggenheim Partners LifeSci Advisors, LLC Cooley LLP Divakar Gupta Richard Segal Wouter Deleersnyder Gide Loyrette Nouel,?Arnaud Duhamel,?Aude-Laurène Dourdain Melanie Simon-Giblin Marie-Hélène (Mariléna) GRYPARIS PwC Philippe Kubisa Arnaud Redouin Alix de Longeaux KPMG Financial Services Philippe Grandclerc Vaea Prior Lison Dahan Chouraki #lifescience?#pharma?#nasdaq?#euronext?#nash

Thoughts on this? >> After 14 years calling partnering shots at Genentech/Roche, James Sabry is headed back into the biotech fray >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharmaceutical #pharma #biotech

?????????????????? ?????? ???????????????????? ???????????????? ?????????????????? ?????????????????????? ???? ?????????????? ???????? ?????????????????? Recursion (Nasdaq: RXRX) Recursion and Exscientia plc (Nasdaq: EXAI) Exscientia have entered into a definitive agreement to combine, creating a leading technology-enabled biotech company. The combined entity will leverage Recursion’s biology and chemistry platform with Exscientia’s precision chemistry tools to accelerate drug discovery and development. Strategic Rationale: Pipeline Synergy: The combination creates a diverse portfolio with 10 expected clinical readouts in the next 18 months. Recursion’s focus on first-in-class candidates complements Exscientia’s best-in-class oncology programs. There is no overlap, ensuring a robust and diversified pipeline. Partnerships: The combined company will have strategic partnerships with leading pharma companies like Roche-Genentech, Sanofi, Bayer, and Merck KGaA, potentially yielding $200 million in milestone payments over the next 2 years. Platform Integration: The integration will form a full-stack technology platform for drug discovery, including automated chemical synthesis, predictive ADMET, and biomarker selection. Transaction Details: Exscientia shareholders will receive 0.7729 shares of Recursion Class A common stock for each Exscientia share. Recursion shareholders will own approximately 74% of the combined company. The combined company holds approximately $850 million in cash and expects to achieve $100 million in annual synergies. The transaction, subject to customary closing conditions, is expected to close by early 2025. #Biotech #DrugDiscovery #PharmaNews #Innovation #Recursion #Exscientia #Healthcare #ClinicalTrials

Thoughts on this? >> After 14 years calling partnering shots at Genentech/Roche, James Sabry is headed back into the biotech fray >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharmaceutical #pharma #biotech #healthcare

Big pharma has gotten serious about TechBio and AI drug discovery, increasing their partnerships and investments ?? We analyzed nine big pharma: Merck, Novo Nordisk, AstraZeneca, Bayer, Bristol Myers Squibb, Sanofi, Novartis, Pfizer, and Boehringer Ingelheim. And mapped 450+ TechBio x Drug Discovery in Europe. ??Most big pharma have placed between three to seven bets in Techbio. The most active pharma have been Merck, Sanofi and Bayer. The startups with the most partnerships/investments are Exscientia, BenevolentAI. What does a partnership deal look like usually? ??In the case of partnerships with AI/computational drug discovery startups, the deal usually looks like this: upfront payment: $30M-60M performance/target-based payments: $500M-$2B Clearly, the upfront commitment for big pharma is not very demanding, and the big payout only happens if targeted outcomes are met. Are big pharma acquiring some of these startups? Mostly not. Partnerships and investments are the preferred route. However, notable exceptions exist, such as InstaDeep acquisition by BioNTech SE. Also notably, Thermo Fisher Scientific (US medical equipment maker) has acquired Olink Proteomics for $3.1B to expand its life sciences portfolio that helps drug discovery. Find out more in the full report by Dealroom.co and Speedinvest in the link below ?? #techbio #drugdiscovery #bigpharma

Thoughts on this? >> BioMarin shakes up executive team, tapping notable dealmaker James Sabry >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #pharmaceutical #pharma #productmarketing

?? Gratitude to our esteemed panel members at the 19th BioPharma Drug Discovery Nexus! Their insights and expertise are shaping the future of drug discovery. Your invaluable insights and expertise have ignited engaging discussions and fueled innovation in the field of drug discovery. #DrugDiscovery #Paneldiscussion #baselevent #BioPharmaNexus #NexusConference #Discoverytools

New: Former Novartis CEO Joe Jimenez and the pharma's long-time research leader Mark Fishman are targeting $400 million for their third fund at Aditum Bio. The Oakland, CA-based firm in-licenses drugs, sets up a company around them and takes the experimental medicines through clinical development toward an M&A exit, like it has done with Versanis Bio, bought by Eli Lilly for up to $1.9 billion last year. Aditum has created 10 companies so far. “I was very clear with all of my investors that out of the 10 companies, I expect only three of them to provide good data, and seven of them will shut down,” Jimenez said in an interview with Endpoints News last fall. “Many times in pharma, if you’re in Phase 2 and you don’t get a positive readout, there’s a project team that’s willing to convince management that all they have to do is change the patient population, and they’re going to have success. That’s not what we’re about.” #biotech #vc #lifesciences #venturecapital #drugdevelopment